Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis

Neurology

Volumn 63, Issue 11 SUPPL. 5, 2004, Pages

  Vartanian, Timothy K ^a,e   Zamvil, Scott S ^b   Fox, Edward ^c   Sorensen, Per Soelberg ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MS Clinic of Central Texas   (United States)

^d Rigshospitalet   (Denmark)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; POLYPEPTIDE; PROTEIN;

ANTIBODY PRODUCTION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; LONG TERM CARE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 10344222630     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.11_suppl_5.s42     Document Type: Review

References (34)

1. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-1740.
2. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Rev Drug Discov 2002;1:457-462.
3. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
4. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
5. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
6. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
7. Salama HH, Hong J, Zang YCQ, El-Mongui A, Zhang J. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003;126:2638-2647.
8. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 1999;10:413-422.
9. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-712.
10. Giovannoni F, Munschauer FE III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469.
11. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024.
12. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-153.
13. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
14. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
15. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
16. OWIMS (Once Weekly Interferon for MS Study Group). Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS Study. Neurology 1999;53:679-686.
17. Rice GPA, Francis GS, and the PRISMS Study Group. Further evidence of dose effect of IFN beta-1a based on neutralizing antibody status. Poster presented at the 11th Annual Meeting of the European Neurological Society, April 21-25, 2001; Paris, France.
18. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496-1504.
19. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
20. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MSCare [serial online] 1999;2:1-6. Available at: http://www.mscare.com. Accessed November 14, 2003.
21. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
22. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517.
23. Clanet M, Kappos L, Hartung H-P, Hohlfeld R, The European IFNβ-1a Dose-Comparison Study Investigators. Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-Comparison Study. Mult Scler 2004;10:139-144.
24. Phillips JT, Rice G, Frohman E, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004;26:511-521.
25. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-1506.
26. Johnson KP, and the U.S. Phase III Copolymer 1 Study Group. Antibodies to copolymer 1 do not interfere with its clinical effect. Ann Neurol 1995;38:973. Abstract.
27. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003;9:592-599.
28. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
29. Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS. Three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-725.
30. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-138.
31. Clanet M, Kappos L, Dong Q, Kooijmans-Coutinho MF, and the The European IFNβ-1a (Avonex) Dose-Comparison Study Investigators. Effect of neutralizing antibodies (NAbs) on the clinical efficacy of interferon β-1a: results from the European Dose-Comparison Study. Poster presented at the 55th Annual Meeting of the American Society of Neurology, March 29-April 5, 2003; Honolulu, HI.
32. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
33. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;251:305-309.
34. Goelz SE. The persistence of neutralizing antibodies to interferon beta (IFNβ) over 6 years of treatment in MS patients is dependent on titer and IFNβ product. Neurology 2004;62 (suppl 5):A156. Abstract.